

Inventor Search101694,448
Cook 101694,432

01/10/2004

=> d ibib abs ind hitstr 17 1-2

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:537491 HCAPLUS
DOCUMENT NUMBER: 135:117260
TITLE: Therapeutic use of D-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation
INVENTOR(S): Campbell, Kathleen C. M.
PATENT ASSIGNEE(S): Southern Illinois University School of Medicine, USA
SOURCE: U.S., 23 pp., Cont.-in-part of U.S. 6,187,817.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6265386	B1	20010724	US 1998-57065	19980408
US 6187817	B1	20010213	US 1997-942845	19971002
PT 1019036	T	20031128	PT 1998-915362	19980408
ES 2202834	T3	20040401	ES 1998-915362	19980408
US 2002019443	A1	20020214	US 2001-911195	20010723
US 2004110719	A1	20040610	US 2003-694448	20031027
US 2004127568	A1	20040701	US 2003-694432	20031027
PRIORITY APPLN. INFO.:			US 1997-942845	A2 19971002
			US 1996-27750P	P 19961003
			US 1998-57065	A2 19980408
			US 2001-911195	A1 20010723

AB Methods of preventing or reducing hearing or balance loss, damage to ear cells, weight loss, gastrointestinal toxicity, neurotoxicity, alopecia, and prolonging survival in patients undergoing treatment with therapeutically effective amts. of platinum-containing chemotherapeutic agents such as cisplatin are provided. Methods are also provided for preventing or reducing such symptoms in patients undergoing treatment with loop diuretics, aminoglycoside antibiotics, iron chelating agents, quinine, and quinidine, or those who have been exposed to toxic levels of noise or radiation. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent, loop diuretic agent, etc., or exposure to noise or radiation. Combinations of these time periods can also be employed.

IC ICM A61K031-70
ICS A61K031-195

NCL 514036000

CC 1-12 (Pharmacology)

Section cross-reference(s): 8

ST methionine cytoprotective ototoxicity drug radiation
noise

IT Antibiotics
(aminoglycoside; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Diuretics
(loop; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Body weight

Hearing

(loss; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Cytoprotective agents

(neuroprotectants; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Toxicity

(neurotoxicity; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Chelating agents

(pharmaceutical; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Antitumor agents

(platinum-containing; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Acoustic noise

Alopecia

Cytoprotective agents

Ear

Radiation

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Digestive tract

Nerve

(toxicity; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT 7439-89-6, Iron, biological studies

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chelating agents; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT 56-54-2, Quinidine 57-92-1, Streptomycin, biological

studies 59-01-8, Kanamycin 114-07-8, Erythromycin

130-95-0, Quinine 1403-66-3, Gentamicin

1404-04-2, Neomycin 1404-90-6, Vancomycin

6379-56-2, Hygromycin 7542-37-2, Paromomycin

14096-51-6, Dichloro(ethylenediamine)platinum(II)

14215-58-8, Chloro(diethylenetriamine)platinum(II) chloride

14913-33-8, trans-Diamminedichloroplatinum(II) 15663-27-1

, Cisplatin 20115-64-4 32986-56-4, Tobramycin

37517-28-5, Amikacin 41575-93-3 41575-94-4,

Carboplatin 41666-77-7 56391-56-1, Netilmicin

62928-11-4, Iproplatin 64363-09-3 67254-31-3

74790-08-2, Spiroplatin 114579-59-8 141610-50-6

148977-78-0 149055-58-3

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT 59-51-8, Methionine 63-68-3, L-Methionine, biological

studies 348-67-4, D-Methionine 502-83-0, Methioninol

1319-79-5 6094-76-4, Homomethionine 13073-35-3

, Ethionine 29908-03-0, S-Adenosyl-L-methionine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT 7439-89-6, Iron, biological studies

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chelating agents; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

RN 7439-89-6 HCAPLUS

CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

IT 56-54-2, Quinidine 57-92-1, Streptomycin, biological

studies 59-01-8, Kanamycin 114-07-8, Erythromycin

130-95-0, Quinine 1403-66-3, Gentamicin

1404-04-2, Neomycin 1404-90-6, Vancomycin

6379-56-2, Hygromycin 7542-37-2, Paromomycin

14096-51-6, Dichloro(ethylenediamine)platinum(II)

14215-58-8, Chloro(diethylenetriamine)platinum(II) chloride

14913-33-8, trans-Diamminedichloroplatinum(II) 15663-27-1

, Cisplatin 20115-64-4 32986-56-4, Tobramycin

37517-28-5, Amikacin 41575-93-3 41575-94-4,

Carboplatin 41666-77-7 56391-56-1, Netilmicin

62928-11-4, Iproplatin 64363-09-3 67254-31-3

74790-08-2, Spiroplatin 114579-59-8 141610-50-6

148977-78-0 149055-58-3


RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

RN 56-54-2 HCAPLUS

CN Cinchonan-9-ol, 6'-methoxy-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 57-92-1 HCAPLUS

CN D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-

(1→2)-O-5-deoxy-3-C-formyl- α -L-lyxofuranosyl-(1→4)-
N,N'-bis(aminoiminomethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-01-8 HCPLUS

CN D-Streptamine, O-3-amino-3-deoxy- α -D-glucopyranosyl-(1→6)-O-[6-amino-6-deoxy- α -D-glucopyranosyl-(1→4)]-2-deoxy- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 114-07-8 HCPLUS

CN Erythromycin (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 130-95-0 HCPLUS

CN Cinchonan-9-ol, 6'-methoxy-, (8 α ,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1403-66-3 HCPLUS

CN Gentamicin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1404-04-2 HCPLUS

CN Neomycin (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1404-90-6 HCPLUS

CN Vancomycin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

-Bu-i

PAGE 2-A




RN 6379-56-2 HCAPLUS

CN D-neo-Inositol, 5-deoxy-5-[(2E)-3-[4-[(6-deoxy- β -D-arabino-hexofuranos-5-ulos-1-yl)oxy]-3-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.




RN 7542-37-2 HCAPLUS

CN D-Streptamine, O-2-amino-2-deoxy- α -D-glucopyranosyl-(1 \rightarrow 4)-O-[O-2,6-diamino-2,6-dideoxy- β -L-idopyranosyl-(1 \rightarrow 3)- β -D-ribofuranosyl-(1 \rightarrow 5)]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 14096-51-6 HCAPLUS

CN Platinum, dichloro(1,2-ethanediamine- κ N, κ N')-, (SP-4-2)- (9CI)
(CA INDEX NAME)


RN 14215-58-8 HCAPLUS

CN Platinum(1+), [N-[2-(amino- κ N)ethyl]-1,2-ethanediamine- κ N, κ N']chloro-, chloride, (SP-4-2)- (9CI) (CA INDEX NAME)


● Cl-

RN 14913-33-8 HCAPLUS


CN Platinum, diamminedichloro-, (SP-4-1)- (9CI) (CA INDEX NAME)



RN 15663-27-1 HCAPLUS
 CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 20115-64-4 HCAPLUS
 CN Platinum(2+), diamminediaqua-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 32986-56-4 HCAPLUS
 CN D-Streptamine, O-3-amino-3-deoxy- α -D-glucopyranosyl-(1 \rightarrow 6)-O-[2,6-diamino-2,3,6-trideoxy- α -D-ribo-hexopyranosyl-(1 \rightarrow 4)]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 37517-28-5 HCAPLUS
 CN D-Streptamine, O-3-amino-3-deoxy- α -D-glucopyranosyl-(1 \rightarrow 6)-O-[6-amino-6-deoxy- α -D-glucopyranosyl-(1 \rightarrow 4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 41575-93-3 HCAPLUS


CN Platinum, diammine[ethylpropanedioato(2-)-κO1,κO3]-, (SP-4-2)-
(9CI) (CA INDEX NAME)

RN 41575-94-4 HCAPLUS

CN Platinum, diammine[1,1-cyclobutanedi(carboxylato-κO) (2-)]-,
(SP-4-2)- (9CI) (CA INDEX NAME)

RN 41666-77-7 HCAPLUS


CN Platinum, (1,2-ethanediamine-κN,κN') [propanedioato(2-)-
κO1,κO3]-, (SP-4-2)- (9CI) (CA INDEX NAME)



RN 56391-56-1 HCPLUS


CN D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-α-D-glycero-hex-4-enopyranosyl-(1→4)]-2-deoxy-N1-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62928-11-4 HCPLUS

CN Platinum, dichlorodihydroxybis(2-propanamine)-, (OC-6-33)- (9CI) (CA INDEX NAME)




RN 64363-09-3 HCPLUS


CN Platinum, aqua(1,2-cyclohexanediamine-κN,κN') [sulfato(2-) - κO]-, (SP-4-3)- (9CI) (CA INDEX NAME)




RN 67254-31-3 HCAPLUS
 CN Platinum, (1,2-cyclohexanediamine- κ N, κ N')bis(2-oxopropanoato- κ O)-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 74790-08-2 HCAPLUS
 CN Platinum, (1,1-cyclohexanedimethanamine- κ N, κ N') [sulfato(2-) - κ O, κ O']-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 114579-59-8 HCAPLUS
 CN Platinum, (1,2-cyclohexanediamine- κ N, κ N') [propanedioato(2-) - κ O1, κ O3]-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 141610-50-6 HCAPLUS
 CN Platinum, (1,2-cyclohexanediamine- κ N, κ N') [ethanedioato(2-) - κ O1, κ O2]-, (SP-4-2)- (9CI) (CA INDEX NAME)



RN 148977-78-0 HCAPLUS

CN Platinato(1-), (1,2-cyclohexanediamine- κ N, κ N') [1-hydroxy-1,2,3-propanetricarboxylato(3-) - κ O1, κ O2] -, hydrogen, (SP-4-3) - (9CI) (CA INDEX NAME)● H⁺

RN 149055-58-3 HCAPLUS

CN Platinato(1-), [1,2,4-benzenetricarboxylato(3-) - κ O1, κ O2] (1,2-cyclohexanediamine- κ N, κ N') -, hydrogen, (SP-4-3) - (9CI) (CA INDEX NAME)● H⁺

IT 59-51-8, Methionine 63-68-3, L-Methionine, biological studies 348-67-4, D-Methionine 502-83-0, Methioninol


1319-79-5 6094-76-4, Homomethionine 13073-35-3
, Ethionine 29908-03-0, S-Adenosyl-L-methionine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

RN 59-51-8 HCAPLUS


CN Methionine (9CI) (CA INDEX NAME)



RN 63-68-3 HCAPLUS

CN L-Methionine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348-67-4 HCAPLUS


CN D-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 502-83-0 HCAPLUS

CN 1-Butanol, 2-amino-4-(methylthio)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1319-79-5 HCAPLUS

CN L-Methionine, hydroxy- (9CI) (CA INDEX NAME)




D1-OH

RN 6094-76-4 HCAPLUS
 CN Norvaline, 5-(methylthio)- (9CI) (CA INDEX NAME)




RN 13073-35-3 HCAPLUS
 CN L-Homocysteine, S-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 29908-03-0 HCAPLUS
 CN Adenosine, 5'-[[[(3S)-3-amino-3-carboxypropyl]methylsulfonio]-5'-deoxy-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:249071 HCAPLUS
 DOCUMENT NUMBER: 130:262147
 TITLE: Use of D-methionine or other methionine compound to reduce the toxicity of ototoxic drugs, noise, and radiation
 INVENTOR(S): Campbell, Kathleen C. M.
 PATENT ASSIGNEE(S): Southern Illinois University, USA
 SOURCE: PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9917765	A1	19990415	WO 1998-US6960	19980408
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6187817	B1	20010213	US 1997-942845	19971002
CA 2303901	AA	19990415	CA 1998-2303901	19980408
AU 9869568	A1	19990427	AU 1998-69568	19980408
AU 753039	B2	20021003		
EP 1019036	A1	20000719	EP 1998-915362	19980408
EP 1019036	B1	20030625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001518499	T2	20011016	JP 2000-514636	19980408
AT 243511	E	20030715	AT 1998-915362	19980408
PT 1019036	T	20031128	PT 1998-915362	19980408
ES 2202834	T3	20040401	ES 1998-915362	19980408
US 1997-942845 A 19971002				
US 1996-27750P P 19961003				
WO 1998-US6960 W 19980408				

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 130:262147

AB Methods of preventing or reducing hearing or balance loss, damage to ear cells, weight loss, gastrointestinal toxicity, neurotoxicity, alopecia, and prolonging survival in patients undergoing treatment with therapeutically effective amts. of platinum-containing chemotherapeutic agents, e.g. cisplatin, are provided. Methods are also provided for preventing or reducing such symptoms in patients undergoing treatment with loop diuretics, aminoglycoside antibiotics, iron chelating agents, quinine, and quinidine, or those who have been exposed to toxic levels of noise or radiation. These methods comprise administering an effective amount of a methionine protective agent, e.g. D-methionine, prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent, loop diuretic agent, etc., or exposure to noise or radiation. Combinations of these time periods can also be employed.

IC ICM A61K031-195
IC S A61K031-10

CC 1-12 (Pharmacology)

Section cross-reference(s): 63

ST methionine protection **ototoxic** drug noise radiation

IT Antibiotics
(aminoglycoside; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and radiation)

IT Digestive tract
(disease; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and radiation)

IT Toxicity
(drug; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and radiation)

IT Drugs
(gastrointestinal; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and radiation)

IT Chelating agents
(iron; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and radiation)

IT Diuretics

(loop; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Alopecia
 Drug delivery systems
 Ear
 Noise
 Radiation
 Radioprotectants
 (methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Toxicity
 (neurotoxicity; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Nerve
 (toxicity; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT 7439-89-6, Iron, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chelating agents; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT 56-54-2, Quinidine 130-95-0, Quinine 15663-27-1
 , Cisplatin
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT 59-51-8, Methionine 59-51-8D, Methionine, compds.
 59-51-8D, Methionine, derivs. 63-68-3, L-Methionine,
 biological studies 63-68-3D, L-Methionine, derivs., biological
 studies 348-67-4, D-Methionine 348-67-4D,
 D-Methionine, derivs. 502-83-0, Methioninol 1319-79-5
 13073-35-3, Ethionine 29908-03-0, S-Adenosyl-L-
 methionine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (methionine compds. to reduce toxicity of **ototoxic** drugs,
 noise, and **radiation**)

IT 7439-89-6, Iron, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chelating agents; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)


RN 7439-89-6 HCPLUS
 CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

IT 56-54-2, Quinidine 130-95-0, Quinine 15663-27-1
 , Cisplatin
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (methionine compds. to reduce toxicity of **ototoxic** drugs,
 noise, and **radiation**)

RN 56-54-2 HCPLUS
 CN Cinchonan-9-ol, 6'-methoxy-, (9S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 130-95-0 HCAPLUS


CN Cinchonan-9-ol, 6'-methoxy-, (8α,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15663-27-1 HCAPLUS

CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)



IT 59-51-8, Methionine 59-51-8D, Methionine, compds.

63-68-3, L-Methionine, biological studies 63-68-3D,

L-Methionine, derivs., biological studies 348-67-4, D-Methionine 348-67-4D, D-Methionine, derivs. 502-83-0, Methioninol

1319-79-5 13073-35-3, Ethionine 29908-03-0,


S-Adenosyl-L-methionine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(methionine compds. to reduce toxicity of ototoxic drugs, noise, and radiation)

RN 59-51-8 HCAPLUS

CN Methionine (9CI) (CA INDEX NAME)




RN 59-51-8 HCAPLUS
 CN Methionine (9CI) (CA INDEX NAME)




RN 63-68-3 HCAPLUS
 CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 63-68-3 HCAPLUS
 CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348-67-4 HCAPLUS
 CN D-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 348-67-4 HCAPLUS
 CN D-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 502-83-0 HCAPLUS

CN 1-Butanol, 2-amino-4-(methylthio)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1319-79-5 HCAPLUS
 CN L-Methionine, hydroxy- (9CI) (CA INDEX NAME)



D1-OH


RN 13073-35-3 HCAPLUS
 CN L-Homocysteine, S-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 29908-03-0 HCAPLUS
 CN Adenosine, 5'-[[[(3S)-3-amino-3-carboxypropyl]methylsulfonio]-5'-deoxy-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
14.86	41.89

Cook 10/694,432

01/10/2004

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.40	-3.50

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:17:31 ON 01 OCT 2004